RBC Capital analyst Conor McNamara maintained a Buy rating on QuidelOrtho (QDEL – Research Report) on January 24 and set a price target of $130.00. The company’s shares closed yesterday at $70.36.
According to TipRanks, McNamara is an analyst with an average return of -10.0% and a 38.81% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for QuidelOrtho with a $89.33 average price target.
See the top stocks recommended by analysts >>
QDEL market cap is currently $4.68B and has a P/E ratio of 360.96.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QuidelOrtho (QDEL) Company Description:
Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.
Read More on QDEL:
